The FDA has accepted BioMarin Pharmaceutical's biologics license application for Vimizim, an enzyme therapy that could be used to treat Mucopolysaccharidosis Type IVA or Morquio A Syndrome, according to Pipeline Review. Mucopolysaccharidosis is a metabolic disorder caused by missing or deficient enzymes needed to break down the keratan sulfate sugar chain. It is physically manifested through skeletal abnormalities, such as a flattening or curvature of the spine and dysplasia of the hips and knees.
Vimizim was also granted a priority review designation, a designation given to drugs that offer major treatment advances, according to the report.
More Articles on Devices:
ECA Medical Instruments Moves Into 24k-Square-Foot Headquarters
K2M Internationally Launches Spinal Device for Small Stature Patients
Spinal Elements Receives Licenses on Portfolio of Lateral Lumbar Spine Approaches
Vimizim was also granted a priority review designation, a designation given to drugs that offer major treatment advances, according to the report.
More Articles on Devices:
ECA Medical Instruments Moves Into 24k-Square-Foot Headquarters
K2M Internationally Launches Spinal Device for Small Stature Patients
Spinal Elements Receives Licenses on Portfolio of Lateral Lumbar Spine Approaches